Raymond James Trust’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-11,282
Closed -$385K 1157
2023
Q2
$385K Hold
11,282
0.01% 777
2023
Q1
$339K Hold
11,282
0.01% 808
2022
Q4
$318K Buy
+11,282
New +$358K 0.01% 791
2022
Q2
Sell
-5,731
Closed -$263K 1089
2022
Q1
$263K Buy
5,731
+362
+7% +$17.3K 0.01% 950
2021
Q4
$329K Sell
5,369
-249
-4% -$17.2K 0.01% 854
2021
Q3
$420K Buy
5,618
+1,934
+52% +$162K 0.01% 689
2021
Q2
$341K Buy
3,684
+550
+18% +$46.8K 0.01% 797
2021
Q1
$278K Buy
+3,134
New +$311K 0.01% 860

Other funds holding ARKG

Raymond James Trust's ARKG Position: Q3 2023 in Review

Raymond James Trust sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2023, closing a stake of 11,282 shares — an estimated $385K sold.

Raymond James Trust first reported a position in ARKG in Q1 2021 and held it in 8 quarters. The position peaked at $420K in Q3 2021. 286 funds tracked by Wall St. Rank hold ARKG as of Q3 2023.

  • Raymond James Trust reported no remaining ARK Genomic Revolution ETF position as of Q3 2023 after selling out during the quarter.
  • Raymond James Trust sold 11,282 ARK Genomic Revolution ETF shares in Q3 2023, an estimated $385K.
  • Raymond James Trust first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 8 quarters.
  • Raymond James Trust's ARK Genomic Revolution ETF position peaked at $420K in Q3 2021.
  • 286 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2023.

Based on Raymond James Trust's 13F filing for Q3 2023, filed 14 Nov 2023.